This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Leukemias/ Lymphomas  • Alert me on articles by topic

Edited by Judith E. Karp.
575 pp, $145.
Totowa, NJ, Humana Press 2007.
ISBN-13 978-1-5882-9621-4.

JAMA. 2007;298(19):2317-2318.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A common complaint about the medical literature that it is difficult to intellectually marry discoveries made in the basic science laboratory with clinical advances. In the field of leukemia, any new textbook must be willing to address the obvious gulf between the growing molecular and genetic understanding of the pathophysiology of the disease and the continued inadequacy of treatments for the majority of adults. In Acute Myelogenous Leukemia, editor Judith Karp—director of the leukemia program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins—articulates this challenge up front, in the introduction: "The aim of Acute Myelogenous Leukemia [AML] is to bring new concepts and findings in the basic and clinical science of AML together ‘under one cover.’" "It is through fluent translation between the laboratory and the clinic that we will be able to change the face of AML from a devastating disease to a highly curable one."

. . . [Full Text of this Article]

Laura C. Michaelis, MD, Reviewer
Division of Hematology/Oncology
Department of Medicine
Loyola University Chicago
Maywood, Illinois
lmichaelis@lumc.edu